Background: To characterize and identify factors associated with the presentation of hyperporgression after initiation of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). Method: A multicenter international retrospective study on 110 patients was conducted. Clinical variables as well as routine blood studies were recorded before initiation of treatment. Regression analysis was used to find associations. A random forest tree analysis (RFTA) based on continuous and discrete variables was used to subcategorize patients based on occurrence of hyperprogression. Results: Median age was 64 years (Range 34-90) and 59.8 % were male patients. ECOG performance status was >1 on 8.8% of patients. Median overall survival was 12.7 months (95% CI 9.67-14 months) and progression-free survival of 4.27 months (95% CI 3.97-5.0). 44 hyperprogressors were documented (19.8%, [95%CI 14.5-25.1%]). Median time to progression was approximately 5 weeks after initiation of treatment. Factors associated included albumin and hemoglobin levels (p ¼ 0.046 and 0.037 respectively), presence of CNS (p¼ 0.0009) and bone metastasis (p ¼ 0.004) and weight loss (p¼ 0.004). RFTA revealed that a leucocyte count over 5.300 cells/dl was present in all hyperprogressors. Conclusion: Hyperprogression is a phenomenon after initiation of immunotherapy which is associated with clinical and paraclinical variables. These associations could be used to withhold certain agents and prevent its occurrence in NSCLC treatment.

(IHC) clone which has higher sensitivity and specificity (SP384) is available. The aim of this study is to compare these ROS1 antibodies and to interpret with FISH results. Method: Twenty-three patients (fourteen ROS1 FISH-positive, nine ROS1 FISH-negative) were included for this study. The material available for all tumors had been formalinfixed and paraffin-embedded (FFPE). D4D6 clone from Cell Signaling Technology and SP384 clone were provided by Ventana Medical Systems, which were used for ROS1 expression. The staining study was performed according to previously published methodology. ROS1 expression was evaluated by intensity scoring. IHC staining patterns of tumor cells was also interpreted as cytoplasmic or membranous and/or both pattern predominantly. All samples of FISH testing has been performed with LSI ROS1 Break Apart Probe; Abbott Molecular probe. Incompatible cases according to FISH and IHC results AmoyDx gene fusions detection kit testing has been used as confirmatory RT-PCR method. Result: See table. Conclusion:-ROS1 SP384 is more feasible then D4D6 for ROS1 protein evaluation. However, both clones may rarely be incompatible with FISH results.-We recommend that the IHC and FISH study should be done together.-In incompatible cases, the RT-PCR study will be determinant with the FISH study.

No abstract

e16573 Background: Ephitelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies among women worldwide. Little is known about reproductive factors or lifestyle determinants and ovarian cancer prognosis. The purpose of this study was to analyze the pathologic, clinical and other characteristics. Methods: This study included all EOC seen at the Institute from 2000–2006. Epidemiological and clinical variables were collected from the patients’ medical records. Exposure data on prediagnostic factors were collected through questionnaires. The cases were followed-up until December 31, 2007. Cox proportional hazard regression model was used to estimate the prognostic effect of each factor in terms of hazard ratios (HR) and 95% confidence intervals (CI), following adjustment for age at diagnosis, FIGO tumor stage and WHO grade of tumor differentiation. Results: 571 cases of ovarian cancers. Median age was 51 years, (range 18–95). 20.30%, 4.4%, and 63.5% of patients had stage I, II and III, respectively. The histological types: 52.2% serous, 17.2% endometrioid, 12.8% of mucinous origin; 62.5% underwent radical surgery, 24% with optimal cytorreduction. The mean follow-up was 60 ± 22 months. The overall three-year survival was 97.4% and 98% for mucinous and serous tumors, respectively. The survival rate was 100%, 90%, and 71.8% in stages I, II and III, respectively. After adjustment for the tumor characteristics, no clear associations were detected between reproductive history, anthropometric characteristics, factors before diagnosis (alcohol consumption, smoking and physical activity over lifetime), nor family history of breast cancer or ovarian cancer and survival Conclusions: Our findings indicate that the tumor characteristics significantly influenced the risk of death from ovarian cancer and no clear associations were detected between others factors and the survival. In this cohort the median age for ovarian cancer were 51 years old, one decade before than other reports. No significant financial relationships to disclose.